SoftWave’s DermaGold® is at the forefront of advanced wound care, utilizing patented technology to stimulate the body’s natural healing process at the cellular level. This breakthrough approach accelerates healing, making it a game-changer in the treatment of various wound types.
SoftWave produces a biological response that accelerates angiogenesis and revascularization which promotes faster wound healing.
Click on the above image to access our White Paper
SoftWave initiates a more rapid and effective healing phase.
It is thought to work by:
Click the image to download the full continuum PDF
DermaGold® offers a superior solution for chronic non-healing wounds with patented technology, leading to better outcomes and higher client satisfaction:
DermaGold® utilizes patented shockwave technology to accelerate natural healing processes at the cellular level, making it a non-invasive, effective treatment for wounds. Unlike traditional therapies, DermaGold® is FDA-cleared for treating Diabetic Foot Ulcers (DFUs), offering a faster, cost-effective solution without the need for a sterile environment. The technology reaches wider and deeper than other options for superior outcomes.
While DermaGold® is FDA-cleared specifically for Diabetic Foot Ulcers, its technology is beneficial for a wide range of wounds. Its non-invasive nature and mechanism of action make it a versatile tool in wound care, suitable for adjunct therapy either alone or in combination with other treatments. It’s advisable to evaluate the specific wound type and condition for compatibility.
Clinics adopting DermaGold® receive comprehensive training and support to ensure seamless integration into their practice. This includes operational training, best practice guidelines, and ongoing clinical support. The goal is to equip clinicians with the knowledge and skills needed to maximize the therapeutic benefits of DermaGold® for their patients.